Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20193405 | 0.91 | TSHR (0.39) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL4776892 | 0.89 | KEAP1 (0.52) | TSHRALDH1A1CYP3A4CYP2D6KEAP1 | |
| SCHEMBL5530538 | 0.85 | CYP3A4 (0.50) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL8952161 | 0.85 | TSHR (0.38) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL28031204 | 0.85 | ESR2 (0.47) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL8952057 | 0.85 | TSHR (0.38) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL13893584 | 0.85 | CYP3A4 (0.50) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2092487 | 0.85 | SMN1; SMN2 (0.46) | TSHRPABPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2099073 | 0.85 | MAPT (0.51) | ALDH1A1CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL18533654 | 0.82 | TSHR (0.36) | TSHRPABPC1ALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3534214-B1 | PROCESS CARTRIDGE AND IMAGE-FORMING APPARATUS | CANON KK (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3534214-A1 | PROCESS CARTRIDGE AND IMAGE-FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3534215-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-20150004341-A1 | THERMOPLASTIC POLYURETHANE AND ASSOCIATED METHOD AND ARTICLE | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2015-01-01 | — | — | US | disclosed |
| WO-2014209934-A1 | THERMOPLASTIC POLYURETHANE AND ASSOCIATED METHOD AND ARTICLE | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2014-12-31 | — | — | WO | disclosed |
| US-7268255-B2 | Process for the preparation of N-substituted formamides | LONZA AG (CH) | 2007-09-11 | — | — | US | disclosed |
| US-20070037985-A1 | Hydrogenating a corresponding nitroarene or nitroheteroarene with formic acid and/or ammonium formate as hydrogen donor and formylating agent in the presence of at least one noble metal-based hydrogenation catalyst and a vanadium or molybdenum compound as co-catalyst | KAMPFEN ULRICH | 2007-02-15 | — | — | US | disclosed |
| EP-1597227-A1 | PROCESS FOR THE PREPARATION OF i N /i -SUBSTITUTED FORMAMIDES | LONZA AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004074234-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED FORMAMIDES | LONZA AG (CH) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037985-A1 | Hydrogenating a corresponding nitroarene or nitroheteroarene with formic acid and/or ammonium formate as hydrogen donor and formylating agent in the presence of at least one noble metal-based hydrogenation catalyst and a vanadium or molybdenum compound as co-catalyst | FH, NIT2, NCF1 | TSHR 3927/4885PABPC1 3947/4885ALDH1A1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.